Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity

  1. Prithvi Raj
  2. Ekta Rai
  3. Ran Song
  4. Shaheen Khan
  5. Benjamin E Wakeland
  6. Kasthuribai Viswanathan
  7. Carlos Arana
  8. Chaoying Liang
  9. Bo Zhang
  10. Igor Dozmorov
  11. Ferdicia Carr-Johnson
  12. Mitja Mitrovic
  13. Graham B Wiley
  14. Jennifer A Kelly
  15. Bernard R Lauwerys
  16. Nancy J Olsen
  17. Chris Cotsapas
  18. Christine K Garcia
  19. Carol A Wise
  20. John B Harley
  21. Swapan K Nath
  22. Judith A James
  23. Chaim O Jacob
  24. Betty P Tsao
  25. Chandrashekhar Pasare
  26. David R Karp
  27. Quan Zhen Li
  28. Patrick M Gaffney
  29. Edward K Wakeland  Is a corresponding author
  1. University of Texas Southwestern Medical Center, United States
  2. Yale School of Medicine, United States
  3. Oklahoma Medical Research Foundation, United States
  4. Université catholique de Louvain, Belgium
  5. Penn State Medical School, United States
  6. Texas Scottish Rite Hospital for Children, United States
  7. Cincinnati Children's Hospital Medical Center, United States
  8. University of Southern California, United States
  9. University of California, Los Angeles, United States

Abstract

Targeted sequencing of sixteen SLE risk loci among 1349 Caucasian cases and controls produced a comprehensive dataset of the variations causing susceptibility to systemic lupus erythematosus (SLE). Two independent disease association signals in the HLA-D region identified two regulatory regions containing 3562 polymorphisms that modified thirty-seven transcription factor binding sites. These extensive functional variations are a new and potent facet of HLA polymorphism. Variations modifying the consensus binding motifs of IRF4 and CTCF in the XL9 regulatory complex modified the transcription of HLA-DRB1, HLA-DQA1 and HLA-DQB1 in a chromosome-specific manner, resulting in a 2.5-fold increase in the surface expression of HLA-DR and DQ molecules on dendritic cells with SLE risk genotypes, which increases to >4-fold after stimulation. Similar analyses of fifteen other SLE risk loci identified 1206 functional variants tightly linked with disease-associated SNPs and demonstrated that common disease alleles contain multiple causal variants modulating multiple immune system genes.

Article and author information

Author details

  1. Prithvi Raj

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Ekta Rai

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Ran Song

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Shaheen Khan

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Benjamin E Wakeland

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Kasthuribai Viswanathan

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Carlos Arana

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Chaoying Liang

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Bo Zhang

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Igor Dozmorov

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Ferdicia Carr-Johnson

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Mitja Mitrovic

    Department of Neurology, Yale School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Graham B Wiley

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Jennifer A Kelly

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Bernard R Lauwerys

    Pole de pathologies rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  16. Nancy J Olsen

    Division of Rheumatology, Department of Medicine, Penn State Medical School, Hershey, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Chris Cotsapas

    Department of Neurology, Yale School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. Christine K Garcia

    Eugene McDermott Center for Human Growth and Development, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  19. Carol A Wise

    Sarah M. and Charles E. Seay Center for Musculoskeletal Research, Texas Scottish Rite Hospital for Children, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  20. John B Harley

    Cincinnati VA Medical Center, Cincinnati Children's Hospital Medical Center, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  21. Swapan K Nath

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  22. Judith A James

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  23. Chaim O Jacob

    Department of Medicine, University of Southern California, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
  24. Betty P Tsao

    Department of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
  25. Chandrashekhar Pasare

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  26. David R Karp

    Rheumatic Diseases Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  27. Quan Zhen Li

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  28. Patrick M Gaffney

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  29. Edward K Wakeland

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    For correspondence
    edward.wakeland@utsouthwestern.edu
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Human subjects: All the study subjects gave their written informed consent for the study. All the research protocols and methods employed were approved by UT Southwestern Institutional Review Board.

Copyright

© 2016, Raj et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,867
    views
  • 1,113
    downloads
  • 112
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Prithvi Raj
  2. Ekta Rai
  3. Ran Song
  4. Shaheen Khan
  5. Benjamin E Wakeland
  6. Kasthuribai Viswanathan
  7. Carlos Arana
  8. Chaoying Liang
  9. Bo Zhang
  10. Igor Dozmorov
  11. Ferdicia Carr-Johnson
  12. Mitja Mitrovic
  13. Graham B Wiley
  14. Jennifer A Kelly
  15. Bernard R Lauwerys
  16. Nancy J Olsen
  17. Chris Cotsapas
  18. Christine K Garcia
  19. Carol A Wise
  20. John B Harley
  21. Swapan K Nath
  22. Judith A James
  23. Chaim O Jacob
  24. Betty P Tsao
  25. Chandrashekhar Pasare
  26. David R Karp
  27. Quan Zhen Li
  28. Patrick M Gaffney
  29. Edward K Wakeland
(2016)
Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity
eLife 5:e12089.
https://doi.org/10.7554/eLife.12089

Share this article

https://doi.org/10.7554/eLife.12089

Further reading

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Stephanie Guillet, Tomi Lazarov ... Frédéric Geissmann
    Research Article

    Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in vivo in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, NRTKs regulate activation, migration, and proliferation of immune cells. We found that the patients’ ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced pluripotent stem cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Dániel Molnár, Éva Viola Surányi ... Judit Toth
    Research Article

    The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.